An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

RAPIVAB®

Drug Information Related Patent

Hold Company

BIOCRYST

Learn More

Dosage and Administration

SOLUTION;INTRAVENOUS

Specification

200MG/20ML (10MG/ML)

Indication

RAPIVAB® is used for the treatment of acute uncomplicated influenza in patients 6 months and older with symptoms of no more than 2 days.

Use

Instructions for Use

API

PERAMIVIR

API Structure

We Supply

PERAMIVIR

Note:

In-house Standard/CP
Facility GMP
KDMF/DMF/WC

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
10391075	2027/2/12
8778997	2027/5/7

API Patent

Patent No	Expiration Date
10391075	2027/2/12
8778997	2027/5/7

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION